Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.
Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.
复制标题
DOI：
--
复制
发表时间：
2000-12
期刊：
影响因子：
--
通讯作者：
W. Symmans;M. Volm;R. Shapiro;A. Perkins;A. Y. Kim;S. Demaria;H. Yee;H. McMullen;R. Oratz;P. Klein;S. Formenti;F. Muggia
中科院分区：
文献类型：
--
作者：
W. Symmans;M. Volm;R. Shapiro;A. Perkins;A. Y. Kim;S. Demaria;H. Yee;H. McMullen;R. Oratz;P. Klein;S. Formenti;F. Muggia
乳腺癌新辅助化疗的肿瘤缩小程度与结果相关。我们研究了紫杉醇的初始细胞反应是否与肿瘤缩小的程度有关。 11 名乳腺癌女性接受紫杉醇（每 2 周一次，共 4 个周期）作为新辅助治疗。在治疗前以及第一次紫杉醇给药后 24、48、72 和 96 小时进行连续细针穿刺活检（FNA；25 号，1 次）。进行细胞凋亡和有丝分裂指数的显微镜计数。使用放射学测量来确定治疗后癌症体积的变化，并考虑到癌症组织病理学数量的变化。细胞凋亡和有丝分裂反应通常在 4 天内消退。对于具有不同治疗结果的女性来说，最初的细胞凋亡反应的持续时间是不同的。前 4 天的累积细胞凋亡反应与新辅助治疗后残留癌症的比例呈负相关。 FNA 是一种获取乳腺癌细胞用于治疗反应研究的多功能临床方法。对第一剂紫杉醇的细胞凋亡反应几乎在 4 天内完成，这意味着更频繁（每周）的紫杉醇给药可能是有益的。对第一剂紫杉醇的细胞凋亡反应似乎可以预测这种治疗的癌症减少量。这是开发用于乳腺癌紫杉醇治疗的早期化学预测测定的一个充满希望的开始。
The extent of tumor reduction from neoadjuvant chemotherapy for breast cancer correlates with outcome. We investigated whether the initial cellular responses to paclitaxel are related to the extent of tumor reduction. Eleven women with breast cancer received paclitaxel (every 2 weeks for 4 cycles) as neoadjuvant treatment. Serial fine-needle aspirations (FNA; 25-gauge, 1 pass) were obtained before treatment and at 24, 48, 72, and 96 h after the first paclitaxel dose. Microscopic counts of apoptotic and mitotic indices were performed. The change in cancer volume from treatment was determined using radiological measurements with allowance for change in the histopathological amount of cancer. Apoptotic and mitotic responses usually subsided within 4 days. The duration of the initial apoptotic response was different for women with different treatment results. Cumulative apoptotic response for the first 4 days inversely correlated with the proportion of residual cancer after neoadjuvant treatment. FNA is a versatile clinical method to obtain breast cancer cells for therapy response studies. Apoptotic response to the first dose of paclitaxel is almost complete within 4 days, implying that more frequent (weekly) paclitaxel dosing might be beneficial. The apoptotic response to the first dose of paclitaxel appeared to predict the amount of cancer reduction from this treatment. This is a promising start toward the development of an early chemopredictive assay for paclitaxel treatment of breast cancer.